Free Trial

Cronos Group (CRON) Competitors

Cronos Group logo
$1.99 +0.02 (+1.02%)
As of 01/17/2025 04:00 PM Eastern

CRON vs. ACAD, MLTX, VCEL, XENE, MOR, SWTX, MRUS, DNLI, BHC, and ZLAB

Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), Vericel (VCEL), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Merus (MRUS), Denali Therapeutics (DNLI), Bausch Health Companies (BHC), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

Cronos Group vs.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings.

ACADIA Pharmaceuticals presently has a consensus target price of $25.25, indicating a potential upside of 43.71%. Cronos Group has a consensus target price of $3.00, indicating a potential upside of 50.75%. Given Cronos Group's higher probable upside, analysts clearly believe Cronos Group is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.59
Cronos Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, ACADIA Pharmaceuticals had 11 more articles in the media than Cronos Group. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 1 mentions for Cronos Group. Cronos Group's average media sentiment score of 1.30 beat ACADIA Pharmaceuticals' score of 0.56 indicating that Cronos Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cronos Group
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ACADIA Pharmaceuticals has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$726.44M4.02-$61.29M$0.7822.53
Cronos Group$87.24M8.72-$73.96M-$0.13-15.31

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Cronos Group's net margin of -42.65%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals13.83% 25.83% 14.71%
Cronos Group -42.65%-2.56%-2.47%

ACADIA Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 6.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals received 429 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.

CompanyUnderperformOutperform
ACADIA PharmaceuticalsOutperform Votes
893
73.14%
Underperform Votes
328
26.86%
Cronos GroupOutperform Votes
464
61.13%
Underperform Votes
295
38.87%

Summary

ACADIA Pharmaceuticals beats Cronos Group on 14 of the 18 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRON vs. The Competition

MetricCronos GroupMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$760.78M$1.22B$5.21B$9.14B
Dividend YieldN/AN/A5.13%4.02%
P/E Ratio-15.3136.3789.3417.36
Price / Sales8.725.591,240.0477.11
Price / CashN/A9.9643.7535.97
Price / Book0.692.045.314.79
Net Income-$73.96M-$53.10M$122.54M$225.00M
7 Day Performance2.05%-1.14%0.59%2.62%
1 Month Performance2.05%-0.47%2.55%3.81%
1 Year Performance-0.50%-5.93%25.29%20.10%

Cronos Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
2.582 of 5 stars
$1.99
+1.0%
$3.00
+50.8%
-0.5%$760.78M$87.24M-15.31450Short Interest ↓
News Coverage
Positive News
ACAD
ACADIA Pharmaceuticals
4.0907 of 5 stars
$17.66
+2.3%
$25.25
+43.0%
-35.6%$2.94B$929.24M22.64510Short Interest ↑
MLTX
MoonLake Immunotherapeutics
1.9821 of 5 stars
$45.82
-1.1%
$81.43
+77.7%
-18.2%$2.93BN/A-35.522Analyst Upgrade
Gap Up
VCEL
Vericel
1.926 of 5 stars
$59.25
-0.4%
$61.14
+3.2%
+48.9%$2.92B$226.84M987.66300Analyst Revision
XENE
Xenon Pharmaceuticals
2.7564 of 5 stars
$38.23
-0.5%
$56.00
+46.5%
-12.0%$2.91B$9.43M-13.56251Positive News
MOR
MorphoSys
0.2266 of 5 stars
$18.96
flat
$14.33
-24.4%
N/A$2.86B$238.28M-5.45730
SWTX
SpringWorks Therapeutics
1.5283 of 5 stars
$38.32
-10.9%
$70.00
+82.7%
-13.1%$2.85B$135.49M-9.88230
MRUS
Merus
3.0447 of 5 stars
$40.64
-7.3%
$85.64
+110.7%
+12.7%$2.78B$35.93M-10.2937High Trading Volume
DNLI
Denali Therapeutics
4.3872 of 5 stars
$19.23
+0.7%
$38.91
+102.3%
+28.3%$2.77B$330.53M-6.97430Short Interest ↑
BHC
Bausch Health Companies
3.3414 of 5 stars
$7.56
-4.1%
$7.75
+2.5%
-8.8%$2.73B$9.47B-15.7520,270Short Interest ↓
Positive News
ZLAB
Zai Lab
2.7048 of 5 stars
$24.97
-1.3%
$55.00
+120.3%
+11.1%$2.73B$355.75M-9.012,175

Related Companies and Tools


This page (NASDAQ:CRON) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners